Meeder Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.53M | Buy |
3,424
+2,799
| +448% | +$1.31M | 0.09% | 135 |
|
|
2025
Q4 | $283K | Buy |
625
+569
| +1,016% | +$245K | 0.02% | 245 |
|
|
2025
Q3 | $21.9K | Hold |
56
| – | – | ﹤0.01% | 415 |
|
|
2025
Q2 | $24.9K | Buy |
56
+9
| +19% | +$4.15K | ﹤0.01% | 480 |
|
|
2025
Q1 | $22.8K | Sell |
47
-26
| -36% | -$12.1K | ﹤0.01% | 518 |
|
|
2024
Q4 | $29.4K | Buy |
73
+2
| +3% | +$927 | ﹤0.01% | 457 |
|
|
2024
Q3 | $33K | Buy |
71
+3
| +4% | +$1.44K | ﹤0.01% | 426 |
|
|
2024
Q2 | $31.9K | Sell |
68
-523
| -88% | -$227K | ﹤0.01% | 423 |
|
|
2024
Q1 | $247K | Buy |
591
+70
| +13% | +$29.6K | 0.02% | 283 |
|
|
2023
Q4 | $212K | Buy |
+521
| New | +$192K | 0.02% | 297 |
|
|
2023
Q3 | – | Sell |
-10,792
| Closed | -$3.8M | – | 590 |
|
|
2023
Q2 | $3.8M | Buy |
10,792
+699
| +7% | +$236K | 0.28% | 80 |
|
|
2023
Q1 | $3.18M | Buy |
10,093
+733
| +8% | +$220K | 0.25% | 93 |
|
|
2022
Q4 | $2.7M | Sell |
9,360
-5,624
| -38% | -$1.71M | 0.24% | 102 |
|
|
2022
Q3 | $4.34M | Buy |
14,984
+5,425
| +57% | +$1.56M | 0.25% | 80 |
|
|
2022
Q2 | $2.69M | Buy |
9,559
+5,536
| +138% | +$1.48M | 0.16% | 123 |
|
|
2022
Q1 | $1.05M | Buy |
+4,023
| New | +$955K | 0.05% | 248 |
|
|
2021
Q4 | – | Sell |
-11,404
| Closed | -$2.07M | – | 2325 |
|
|
2021
Q3 | $2.07M | Buy |
11,404
+9,581
| +526% | +$1.87M | 0.11% | 160 |
|
|
2021
Q2 | $368K | Sell |
1,823
-13,949
| -88% | -$2.92M | 0.02% | 589 |
|
|
2021
Q1 | $3.39M | Buy |
15,772
+14,221
| +917% | +$3.12M | 0.17% | 120 |
|
|
2020
Q4 | $367K | Sell |
1,551
-16,101
| -91% | -$3.69M | 0.08% | 200 |
|
|
2020
Q3 | $4.8M | Buy |
17,652
+286
| +2% | +$78.9K | 0.31% | 72 |
|
|
2020
Q2 | $5.04M | Buy |
17,366
+929
| +6% | +$252K | 0.33% | 63 |
|
|
2020
Q1 | $3.91M | Sell |
16,437
-28,596
| -64% | -$6.56M | 0.3% | 76 |
|
|
2019
Q4 | $9.86M | Sell |
45,033
-973
| -2% | -$197K | 0.6% | 43 |
|
|
2019
Q3 | $7.79M | Buy |
46,006
+982
| +2% | +$174K | 0.52% | 63 |
|
|
2019
Q2 | $8.26M | Buy |
45,024
+4,513
| +11% | +$789K | 0.58% | 52 |
|
|
2019
Q1 | $7.45M | Buy |
40,511
+5,085
| +14% | +$939K | 0.59% | 47 |
|
|
2018
Q4 | $5.87M | Buy |
35,426
+6,159
| +21% | +$1.07M | 0.52% | 53 |
|
|
2018
Q3 | $5.64M | Sell |
29,267
-194
| -0.7% | -$34.5K | 0.42% | 70 |
|
|
2018
Q2 | $5.01M | Buy |
29,461
+9,187
| +45% | +$1.42M | 0.43% | 69 |
|
|
2018
Q1 | $3.31M | Buy |
20,274
+9,079
| +81% | +$1.48M | 0.31% | 82 |
|
|
2017
Q4 | $1.68M | Sell |
11,195
-1,313
| -10% | -$194K | 0.14% | 145 |
|
|
2017
Q3 | $1.9M | Buy |
12,508
+840
| +7% | +$126K | 0.21% | 130 |
|
|
2017
Q2 | $1.5M | Buy |
+11,668
| New | +$1.4M | 0.14% | 147 |
|
|
2016
Q4 | – | Sell |
-1,235
| Closed | -$107K | – | 1063 |
|
|
2016
Q3 | $107K | Buy |
+1,235
| New | +$117K | 0.01% | 594 |
|
|
2015
Q2 | – | Sell |
-15,135
| Closed | -$1.79M | – | 532 |
|
|
2015
Q1 | $1.79M | Buy |
+15,135
| New | +$1.81M | 0.19% | 160 |
|
Other funds holding VRTX
VCM
VPM
Meeder Asset Management's VRTX Position: Q1 2026 in Review
Meeder Asset Management increased its Vertex Pharmaceuticals (VRTX) stake by 448% in Q1 2026, buying an estimated $1.31M and bringing the position to 3,424 shares worth $1.53M. The position accounts for 0.09% of the portfolio, ranked #135.
Meeder Asset Management first reported a position in VRTX in Q1 2015 and has held it in 36 quarters since. The position peaked at $9.86M in Q4 2019. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Meeder Asset Management held 3,424 shares of Vertex Pharmaceuticals worth $1.53M as of Q1 2026.
- Meeder Asset Management bought 2,799 Vertex Pharmaceuticals shares in Q1 2026, an estimated $1.31M.
- Vertex Pharmaceuticals made up 0.09% of Meeder Asset Management's portfolio in Q1 2026, its #135 holding.
- Meeder Asset Management first reported a position in Vertex Pharmaceuticals in Q1 2015 and has held it in 36 quarters since.
- Meeder Asset Management's Vertex Pharmaceuticals position peaked at $9.86M in Q4 2019.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Meeder Asset Management's 13F filing for Q1 2026, filed 7 May 2026.